Understanding Messenger RNA and Other SARS-CoV-2 Vaccines
On January 15, 2021
In mid-November, Pfizer/BioNTech were the first with surprising positive protection interim data for their coronavirus vaccine, BNT162b2. A week later, Moderna released interim efficacy results showing its coronavirus vaccine, mRNA-1273, also protected patients from developing SARS-CoV-2 infections.
Patient Education, Healthcare Providers, Payer/Health Plans, COVID-19